NCT07695493

Brief Summary

Assess the quality of care and the satisfaction of patients and caregivers when the monitoring of people on HIV pre-exposure prophylaxis (PrEP) is provided by nurses instead of physicians

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
504

participants targeted

Target at P75+ for not_applicable

Timeline
27mo left

Started Sep 2026

Typical duration for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 6, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 10, 2026

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2028

3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

July 10, 2026

Status Verified

July 1, 2026

Enrollment Period

2 years

First QC Date

July 6, 2026

Last Update Submit

July 6, 2026

Conditions

Keywords

HIV infectionPre exposure Prophylaxis (PrEP)

Outcome Measures

Primary Outcomes (1)

  • Compliance to PrEP

    Compliance to PrEP is defined by a composite criterion comprising: * Presence at scheduled follow-up visits at 0, 6, and 12 months AND * Undergoing an HIV screening test before each visit to allow for the prescription of PrEP if the result is negative (+/-14 days) AND * Prescription of PrEP at each visit

    Up to 12 months

Secondary Outcomes (11)

  • Occurrence of sexually transmitted infection (STI)

    At baseline

  • Occurrence of sexually transmitted infection (STI)

    At 6 months

  • Occurrence of sexually transmitted infection (STI)

    At 12 months

  • Tolerability of PrEP

    At baseline

  • Tolerability of PrEP

    At 6 months

  • +6 more secondary outcomes

Study Arms (2)

Follow-up visits for PrEP prescription conducted by a physician.

ACTIVE COMPARATOR
Other: Monitoring of PrEP by physicians

Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.

EXPERIMENTAL
Other: Monitoring of PrEP by nurses

Interventions

Monitoring of PrEP by nurses

Follow-up visits for PrEP prescription conducted by a nurse under the same conditions.

Monitoring of PrEP by physicians

Follow-up visits for PrEP prescription conducted by a physician.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male sex assigned at birth, aged ≥ 18 years
  • Individual at risk of HIV infection
  • Currently receiving PrEP care and willing to continue follow-up in a hospital setting
  • Receiving care at a hospital setting by a physician and not objecting to follow-up by a nurse
  • Having received complete information about the study and having provided a free written informed consent
  • Affiliated with a social security system (beneficiary or entitled individual) or covered by State Medical Aid (AME).

You may not qualify if:

  • Individual with confirmed HIV infection
  • Currently receiving nurse care in a hospital setting
  • Having renal impairment (creatinine clearance \< 60 mL/min)
  • Unable to provide informed consent
  • Not affiliated with a social security system or not covered by State Medical Aid (AME)
  • Under legal guardianship or curatorship
  • Deprived of liberty by judicial or administrative decision, or individuals receiving psychiatric care under Article L1121-6 of the French Public Health Code

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Central Study Contacts

Bénédicte Loze, Nurse

CONTACT

Jérôme Lambert, MD PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: A pragmatic, randomized, controlled, multicenter, open-label, two-arm parallel-group, non-inferiority trial.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 6, 2026

First Posted

July 10, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

July 10, 2026

Record last verified: 2026-07